Business
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Thursday, September 28, 2023 at 3:00pm Eastern Time.\n\n\nA live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at https://xerispharma.com/investor-relations or https://wsw.com/webcast/cantor19/xers/2124738\n\n\nA replay of the webcast will be available for 60 days.\n\n\nAbout Xeris\n\n\nXeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect™, to support long-term product development and commercial success.\n\n\nXeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230914198760/en/\n\nInvestor Contact\nAllison Wey\nSenior Vice President, Investor Relations and Corporate Communications\[email protected]\n\n\nSource: Xeris Biopharma Holdings, Inc.","length":4460,"tagName":"div"}]